SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Dysexecutive Syndrome: Diagnostic Criteria and Validation Study
Ann Neurol 68:855-864, Godefroy,O.,et al, 2010
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Pract Neurology 4:50-55, Razvi,S.S.M. &Muir,K.W., 2004
Diffusion-Weighted Imaging Discriminates Progressive Supranuclear Palsy from PD, But Not From the Parkinson Variant of Multiple System Atrophy
Neurol 60:922-927, Seppi,K.,et al, 2003
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Consensus Guidelines for Clin & Path Dx of Dementia with Lewy Bodies (DLB) :Report of DLB Intl Workshop
Neurol 47:1113-1114, 11241996., McKeith,I.G.,et al, 1996
Cigarette Smoking and Protection from Parkinson's Disease:False Association or Etiologic Clue?
Neurol 45:1041-1051, Morens,D.M.,et al, 1995
Progressive Supranuclear Palsy:Neuropathologic and Clinical Heterogeneity
Neurol 44:1015-1024, Gearing,M.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Turning Slowly Predicts Future Diagnosis of Parkinsons Disease:A Decade-Long Longitudinal Analysis
Ann Neurol 99:114-123, Elshehabi,M.,, 2026
Restless Legs Syndrome, A Review
JAMA 335:703-714, Winkelmen,J.W. & Wipper, B., 2026
Association of Coffee Consumption and Prediagnostic Caffeine Metabolites with Incident Parkinson Disease in a Population-Based Cohort
Neurol 102:e209201, Zhao,Y.,et al, 2024
Cutaneous a-Synuclein Signatures in Patients with MultipleSystem Atrophy and Parkinson Disease
Neurol 100:e1529-e1539, Gibbons,C.,et al, 2023
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Serum NFL discriminates Parkinson Disease from Atypical Parkinsonisms
Neurol 92:e1479-e1486, Marques, T.M.,et al, 2019
Placebo-Controlled, Randomized, Double-Blind Study of IncobotulinumtoxinA for Sialorrhea
Neurol 92:e1982-e1991, Jost, W.H.,et al, 2019
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients with Medication-Refractory, Tremor-Dominant Parkinson Disease
JAMA Neurol 74:1412-1418, Bond, A.E.,et al, 2017
Exploring the Association Between Rosacea and Parkinson Disease
JAMA Neurol 73:529-534, Egeberg, A.,et al, 2016
Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of DIagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality
AJNR 36:2010-2016, Noh, Y.,et al, 2015
Parkinson Disease Subtypes
JAMA 71:499-504, Thenganatt, M. & Jankovic, J., 2014
Skin Nerve (-Synuclein Deposits
Neurol 82:1362-1369, Donadio, V.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Parkinsonism is a Late, Not Rare, Feature of CADASIL
Stroke 44:1147-1149, Ragno, M.,et al, 2013
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Role of Brain Imaging in Early Parkinsonism
BMJ 324:d638, Breen,D.P.,et al, 2011
High-Resolution Diffusion Tensor Imaging in the Substantia Nigra of De Novo Parkinson Disease
Neurol 72:1378-1384,1374, Vaillancourt,D.E.,et al, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Increased Risk of Parkinsonism in Women Who Underwent Oophorectomy Before Menopause
Neurol 70:200-209, Rocca,W.A.,et al, 2008
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Attempted and Completed Suicides After Subthalamic Nucleus Stimulation for Parkinsons Disease
JNNP 79:952-954, Soulas,T.,et al., 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007